Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
作者: Shannon L. ReynoldsSameer R. GhateRichard SheerPranav K. GandhiChad MoretzCheng WangStephen SanderMary E. CostantinoSrinivas AnnavarapuGeorge Andrews
作者单位: 1Comprehensive Health Insights
2Boehringer Ingelheim
3Humana Inc
刊名: Health and Quality of Life Outcomes, 2017, Vol.15 (1)
来源数据库: Springer Journal
DOI: 10.1186/s12955-017-0705-x
关键词: DabigatranWarfarinHealthcare resource utilizationNon-valvular atrial fibrillation
英文摘要: Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study expands on previous work by comparing HCRU and costs for patients newly diagnosed with NVAF and newly initiated on dabigatran or warfarin, and is the first study specifically in a Medicare population.
原始语种摘要: Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study expands on previous work by comparing HCRU and costs for patients newly diagnosed with NVAF and newly initiated on dabigatran or warfarin, and is the first study specifically in a Medicare population.
全文获取路径: Springer  (合作)
分享到:
来源刊物:
影响因子:2.272 (2012)

×
关键词翻译
关键词翻译
  • fibrillation 原纤维化
  • atrial 围鳃的
  • warfarin 杀鼠灵
  • valvular 壳瓣的
  • utilization 利用
  • costs 费用
  • initiating 启动
  • stroke 笔划
  • together 共同
  • newly 重新